ArticleFrontiers in endocrinology2024
Association of circulating adiponectin and leptin levels with the risk of diabetic peripheral neuropathy.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pain mechanisms in osteoarthritis: recent discoveries and opportunities ahead.Connective tissue research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adipokines have been implicated in the pathogenesis of type 2 diabetes mellitus (T2DM) and related complications due to their roles in metabolic regulation and inflammation. However, the relationship between these adipokines and diabetic peripheral neuropathy (DPN) remains unclear. Methods: A case-control study was performed with 198 patients with DPN and 205 T2DM patients without DPN from the Endocrinology Department at the Second Affiliated Hospital of Hainan Medical University. Circulating adiponectin and leptin levels were quantified via enzyme-linked immunosorbent assays. Logistic regression models, adjusting for age, sex, BMI, smoking status, and diabetes duration, were applied to evaluate the associations between adiponectin and leptin levels and DPN risk. Results: DPN patients exhibited lower adiponectin (P=0.001) and higher leptin (P=0.007) levels than diabetic controls. Confounders-adjusted analyses revealed that higher adiponectin levels correlated with reduced DPN risk (OR, tertile 3 vs. tertile 1: 0.52; 95% CI: 0.30-0.90), whereas elevated leptin levels were linked to increased DPN risk (OR, tertile 3 vs. tertile 1: 1.91; 95% CI: 1.10-3.32). Stratified analyses confirmed consistent findings across subgroups without statistically significant interactions. Conclusions: Circulating adiponectin and leptin levels correlate with DPN risk in diabetic patients, suggesting their potential as biomarkers for high-risk DPN identification and guiding targeted prevention and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.